Frontlight ResearchEarly access
WithdrawnPhase 2
A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With Nonalcoholic Fatty Liver Disease
Key facts
- Who runs it
- The University of Texas Health Science Center, Houston
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 1 Dec 2023
- Ended
- 1 Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- PRIM-DJ2727
- Placebo
- Record updated
- 14 May 2024
- Why it stopped
- lack of funds
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- ≥ 18 years of age
- For sexually active male and female subjects of childbearing potential, agree to use an effective method of birth control during the study
- For female subjects of childbearing potential, a negative urine Qualitative HCG pregnancy test at enrollment and on the Week 1, Day 1 of the Treatment prior to administration of study drug
- Willing and able to sign an informed consent form and attend study assessments and follow up visits
- A documented diagnosis of NAFLD without cirrhosis based on imaging or clinical judgment of a gastroenterologist or hepatologist
- History of diabetes mellitus
- Has an attending physician who will provide non-transplant care for the subject
- Agrees to maintain a stable regimen including weight loss, exercise, medications to control lipids and glucose, and vitamin E therapy if already prescribed, during participation in the study
Who cannot take part
- Receipt of systemic non-topical antibiotic therapy within 14 days of treatment day 1
- History of use of an investigational drug within 90 days prior to the screening visit
- Compromised immune system (e.g. primary immune disorders or clinical immunosuppression due to a medical condition or medication e.g. taking oral prednisone >20 mg a day or prednisone-equivalent)
- Positive results for active HIV, Hepatitis B, or Hepatitis C infections
- Current history for active states of Inflammatory bowel disease, Irritable bowel syndrome, microscopic colitis, celiac disease, short gut syndrome, colostomy, colectomy, gastrointestinal fistulae or strictures
- History of significant uncontrolled systemic disease that in the opinion of the study investigator could interfere with study participation and/or objectives
- Unable to take multiple capsules orally
- Alcohol consumption of greater than an average of one drink per day for women and two drinks per day for men
- Hemochromatosis
- Hepatic encephalopathy
- Life expectancy of < 1 year
- In the opinion of investigator, subject for any reason, should be excluded from the study
About the trial
What the trial wants to find out
Potential subjects with non-alcoholic fatty liver disease (NAFLD) will be identified by gastroenterologists (study investigators). Twelve eligible subjects with NAFLD will be randomly assigned to receive either active fecal microbiota transplantation in orally administered capsules or Placebo capsules and dosed twice weekly for 12 weeks. .
The 2 groups in the trial
- Active groupTreatment being tested
Patients with NAFLD will receive orally fecal microbiota capsules from healthy donors
Treatment: PRIM-DJ2727
- Placebo groupPlacebo, for comparison
Placebo capsules will be identical to the active capsules, but not contain intestinal bacteria
Treatment: Placebo
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Nonalcoholic Fatty Liver Disease (NAFLD)
- Record updated
- 14 May 2024